Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Y-27632 dihydrochloride: Selective ROCK Inhibitor for Cyt...

    2025-11-13

    Y-27632 dihydrochloride: Selective ROCK Inhibitor for Cytoskeletal and Cancer Research

    Executive Summary: Y-27632 dihydrochloride is a cell-permeable, small-molecule inhibitor that selectively targets ROCK1 and ROCK2, with IC50 values of approximately 140 nM and 300 nM, respectively (APExBIO, product page). The compound disrupts Rho-mediated stress fiber formation and modulates cell cycle progression, as verified in both in vitro and in vivo models (Linxweiler et al., 2018). Y-27632 preserves stem cell viability and enhances the formation and maintenance of patient-derived 3D organoid cultures (Linxweiler et al., 2018). The compound is highly soluble in DMSO, ethanol, and water, streamlining integration into cell culture workflows (APExBIO, product documentation). Its utility is confirmed in prostate cancer models and stem cell platforms, with reliable storage and handling parameters.

    Biological Rationale

    Y-27632 dihydrochloride is a selective ROCK inhibitor designed to modulate the Rho/ROCK signaling pathway. Rho-associated kinases (ROCK1/2) are serine/threonine kinases that regulate actin cytoskeletal dynamics, stress fiber formation, and cellular contractility. Dysregulated ROCK signaling is implicated in tumor invasion, metastasis, and abnormal cell proliferation (Linxweiler et al., 2018). Selective inhibition of ROCK1/2 allows precise manipulation of cell shape, motility, and cell cycle processes in both basic and translational research contexts. Y-27632 is widely used to enhance the viability of stem cells, including human pluripotent stem cells, and to suppress apoptosis during cell dissociation (See also: CY5-5 NHS Ester resource—this article extends the practical applications into new 3D models and cancer research).

    Mechanism of Action of Y-27632 dihydrochloride

    Y-27632 dihydrochloride binds competitively to the ATP-binding site of ROCK1 and ROCK2 catalytic domains. The reported IC50 for ROCK1 is approximately 140 nM, and for ROCK2, the Ki is 300 nM (APExBIO, product page). The compound demonstrates over 200-fold selectivity for ROCK over other kinases such as PKC, PKA, MLCK, and PAK. By inhibiting ROCK, Y-27632 prevents phosphorylation of downstream targets like myosin light chain (MLC), leading to reduced actomyosin contractility, impaired stress fiber formation, and altered focal adhesion dynamics (Contrast: AS602801—focuses on cytoskeletal dissection; this article adds cancer and organoid context).

    Cellular effects include:

    • Suppression of Rho-mediated stress fiber and focal adhesion assembly
    • Modulation of cell cycle progression, notably the G1/S transition
    • Inhibition of cytokinesis and reduced proliferation in smooth muscle and cancer cell lines
    • Enhanced survival and maintenance of stem cells and tissue-derived organoids

    Evidence & Benchmarks

    • Y-27632 dihydrochloride inhibits ROCK1 with an IC50 of 140 nM and ROCK2 with a Ki of 300 nM (APExBIO, product documentation).
    • It is >200-fold selective versus PKC, PKA, MLCK, and PAK, minimizing off-target kinase inhibition (Reference: Mouse IFN-α—this article provides new solubility/storage data).
    • In patient-derived 3D prostate cancer spheroid cultures, Y-27632 enhances spheroid viability and maintenance over several months (Linxweiler et al., 2018).
    • In vitro, Y-27632 reduces proliferation of prostatic smooth muscle cells in a concentration-dependent manner (Linxweiler et al., 2018).
    • In mouse models, Y-27632 inhibits tumor invasion and metastasis by disrupting pathological actin structures (Linxweiler et al., 2018).
    • Solubility benchmarks: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water at 37°C (APExBIO, product page).

    Applications, Limits & Misconceptions

    Y-27632 dihydrochloride is extensively used in:

    • Stem cell culture, to enhance viability and reduce apoptosis during passaging or cryopreservation (See also: Y-27632.com resource—this article clarifies cancer and organoid benchmarks).
    • Cancer biology, to suppress tumor cell invasion, migration, and metastasis in vitro and in vivo.
    • Organoid and 3D spheroid culture systems derived from patient tissue samples, enabling translational modeling of tumor microenvironments (Linxweiler et al., 2018).
    • Dissection of cytoskeletal regulation and Rho/ROCK pathway signaling.

    Common Pitfalls or Misconceptions

    • Y-27632 is not effective against non-ROCK kinases at standard working concentrations; off-target effects are minimal but possible at high doses.
    • Long-term storage of Y-27632 solutions is discouraged due to potential degradation; prepare fresh aliquots for critical experiments.
    • It does not induce differentiation of stem cells; it primarily enhances survival and suppresses apoptosis.
    • Y-27632 does not reverse established fibrosis or tumor burden; its effects are preventive/modulating rather than curative.
    • The compound is not a substrate-specific inhibitor; it broadly blocks ROCK1/2 catalytic activity.

    Workflow Integration & Parameters

    Solubility and Preparation: Y-27632 dihydrochloride is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water. Warming to 37°C or using an ultrasonic bath can enhance dissolution. Stock solutions should be stored below -20°C and protected from moisture (APExBIO, product documentation).

    Experimental Design: For in vitro applications, typical working concentrations range from 1 μM to 50 μM, adjusted according to cell type and objective. For stem cell viability, 10 μM is commonly used; for cytoskeletal studies, titration may be necessary. Include appropriate vehicle controls (e.g., DMSO-only) in every experiment.

    Storage: Y-27632 is supplied as a solid and should be kept desiccated at 4°C or below. Aliquots of stock solutions should be freshly thawed for each use to minimize freeze-thaw cycles.

    Conclusion & Outlook

    Y-27632 dihydrochloride (APExBIO A3008) is a well-characterized, potent, and selective ROCK1/2 inhibitor with broad utility across cytoskeletal, stem cell, and cancer research domains. Its robust selectivity and reproducibility make it indispensable for dissecting the Rho/ROCK signaling pathway and for enhancing the viability of sensitive cell types. Future research will likely extend its integration into next-generation organoid, regenerative, and translational disease models (See also: ABT-737—focuses on cytoskeletal modulation; this article adds cancer and storage best-practices). For ordering and further technical details, see the Y-27632 dihydrochloride product page.